Wilmington Savings Fund Society FSB Makes New $193,000 Investment in ResMed Inc. (NYSE:RMD)

Wilmington Savings Fund Society FSB acquired a new stake in ResMed Inc. (NYSE:RMD) in the third quarter, HoldingsChannel.com reports. The firm acquired 789 shares of the medical equipment provider’s stock, valued at approximately $193,000.

Other large investors have also modified their holdings of the company. Versor Investments LP raised its position in ResMed by 327.3% in the 2nd quarter. Versor Investments LP now owns 4,700 shares of the medical equipment provider’s stock valued at $900,000 after purchasing an additional 3,600 shares during the last quarter. Retireful LLC purchased a new stake in shares of ResMed in the third quarter valued at about $742,000. Asset Management One Co. Ltd. boosted its stake in shares of ResMed by 5.1% during the third quarter. Asset Management One Co. Ltd. now owns 58,860 shares of the medical equipment provider’s stock worth $14,369,000 after buying an additional 2,878 shares during the period. Empowered Funds LLC grew its holdings in shares of ResMed by 284.3% during the third quarter. Empowered Funds LLC now owns 8,208 shares of the medical equipment provider’s stock worth $2,004,000 after buying an additional 6,072 shares during the last quarter. Finally, Ensign Peak Advisors Inc grew its holdings in shares of ResMed by 18.4% during the second quarter. Ensign Peak Advisors Inc now owns 85,710 shares of the medical equipment provider’s stock worth $16,407,000 after buying an additional 13,324 shares during the last quarter. 54.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

RMD has been the topic of a number of recent research reports. Robert W. Baird boosted their target price on ResMed from $280.00 to $283.00 and gave the company an “outperform” rating in a report on Friday, October 25th. StockNews.com upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. Bank of America boosted their target price on ResMed from $240.00 to $270.00 and gave the stock a “buy” rating in a research report on Thursday, September 26th. KeyCorp raised their price target on ResMed from $251.00 to $266.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Finally, Stifel Nicolaus began coverage on ResMed in a report on Friday, December 13th. They set a “hold” rating and a $250.00 price objective on the stock. One analyst has rated the stock with a sell rating, six have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, ResMed has a consensus rating of “Moderate Buy” and an average target price of $227.91.

Insider Buying and Selling

In other ResMed news, CEO Michael J. Farrell sold 14,683 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $231.91, for a total transaction of $3,405,134.53. Following the completion of the transaction, the chief executive officer now owns 464,169 shares of the company’s stock, valued at approximately $107,645,432.79. This trade represents a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Brett Sandercock sold 1,000 shares of the company’s stock in a transaction on Tuesday, October 8th. The shares were sold at an average price of $233.47, for a total value of $233,470.00. Following the completion of the sale, the chief financial officer now owns 95,812 shares in the company, valued at $22,369,227.64. This represents a 1.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 47,725 shares of company stock worth $11,253,448 in the last ninety days. Insiders own 0.71% of the company’s stock.

ResMed Stock Down 5.1 %

RMD opened at $230.21 on Thursday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.91 and a current ratio of 2.92. The company has a market cap of $33.79 billion, a price-to-earnings ratio of 30.49, a PEG ratio of 1.73 and a beta of 0.68. ResMed Inc. has a one year low of $164.12 and a one year high of $260.49. The business’s fifty day moving average is $242.91 and its two-hundred day moving average is $228.23.

ResMed (NYSE:RMD) last released its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 EPS for the quarter, topping the consensus estimate of $2.03 by $0.17. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The business had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.19 billion. During the same period in the previous year, the firm earned $1.64 EPS. The business’s revenue for the quarter was up 11.1% compared to the same quarter last year. Analysts anticipate that ResMed Inc. will post 9.34 EPS for the current fiscal year.

ResMed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, December 12th. Stockholders of record on Thursday, November 7th were paid a dividend of $0.53 per share. The ex-dividend date of this dividend was Thursday, November 7th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.92%. ResMed’s dividend payout ratio (DPR) is 28.08%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.